Skip to main content
Autobound logo

What Viatris's latest 10-Q says: 7 signals

Viatris filed its latest 10-Q with the SEC on Aug 6, 2026. It discusses automation investment, capex increase and competitor named.

Public (VTRS)Pharmaceutical Manufacturing10,000+ employeesviatris.comLinkedIn

Filed
Aug 6, 2026
Filings
2
Signals
17

10-Q · latest 10

What Viatris's 10-Q filings say

  1. 10-Q

    Filed · 7 signals

    SEC EDGAR

  2. 10-Q

    Filed · 10 signals

    SEC EDGAR

Showing 10 of 17 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Viatris earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Launching enterprise-wide strategic review to find meaningful cost savingsA major strategic review is underway to identify significant, multi-year net cost savings across commercial, R&D, manufacturing, and corporate functions, creating opportunities for consulting and technology vendors.
Actively exploring partnerships for new non-opioid pain drug launchManagement is in discussions with potential partners to expand the commercial reach for fast-acting meloxicam, creating a direct opportunity for contract sales organizations or co-promotion partners.
Raised full-year guidance for revenue, adjusted EBITDA, and adjusted EPSThe company has increased its financial outlook for the year, signaling strong business performance and confidence in meeting financial targets. This financial health supports their ability to invest in new projects and vendors.
R&D spending is increasing to accelerate key clinical trial programsOperating expenses reflect higher R&D spending due to accelerated enrollment in late-stage clinical trials for selatogrel and cenerimod. This indicates budget allocation towards R&D operations, clinical trial management solutions, and data analysis platforms.
Expanding presence in Japan through the acquisition of Aculys PharmaThe acquisition of Aculys Pharma strengthens Viatris's portfolio and infrastructure in Japan, a key strategic market. This expansion and integration create needs for regional-specific marketing, regulatory, and operational support.
Prioritizing capital return to shareholders with over $1B commitmentThe company has returned over $920M YTD and is on track for over $1B, leaning into buybacks. This may signal a heightened focus on cost-efficiency and ROI for any new vendor investments.

Signal API · MCP

Track Viatris with the Signal API

One POST /v1/companies/enrich call with viatris.com returns Viatris 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"viatris.com","signal_types":["sec-10q"],"limit":20}'

Same industry

10-Q at related companies

Questions about Viatris 10-Q

When did Viatris file its latest 10-Q?
Viatris filed its latest 10-Q on Aug 6, 2026. The one before it was filed on May 7, 2026.
What did Viatris disclose in its latest 10-Q?
From the filing dated Aug 6, 2026: Viatris in payment dispute with Pfizer over opioid-related liabilities
What did Viatris say on its recent earnings calls?
Q3 FY2025: Launching enterprise-wide strategic review to find meaningful cost savings (dated Nov 6, 2025).
Where can I read Viatris's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →